122 related articles for article (PubMed ID: 11725207)
1. Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat.
Roberts MS; Wu ZY; Siebert GA; Thompson JF; Smithers BM
Melanoma Res; 2001 Dec; 11(6):611-8. PubMed ID: 11725207
[TBL] [Abstract][Full Text] [Related]
2. Isolated limb perfusion with melphalan for human melanoma xenografts in the hindlimb of nude rats: a surviving animal model.
Wu Z; Roberts MS; Parsons PG; Smithers BM
Melanoma Res; 1997 Feb; 7(1):19-26. PubMed ID: 9067961
[TBL] [Abstract][Full Text] [Related]
3. Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb.
Wu ZY; Smithers BM; Roberts MS
Melanoma Res; 1997 Jun; 7(3):252-64. PubMed ID: 9195565
[TBL] [Abstract][Full Text] [Related]
4. Melphalan in regional chemotherapy for locally recurrent metastatic melanoma.
Defty CL; Marsden JR
Curr Top Med Chem; 2012; 12(1):53-60. PubMed ID: 22196271
[TBL] [Abstract][Full Text] [Related]
5. Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma?
Huismans AM; Kroon HM; Haydu LE; Kam PC; Thompson JF
Ann Surg Oncol; 2012 Sep; 19(9):3050-6. PubMed ID: 22526898
[TBL] [Abstract][Full Text] [Related]
6. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.
Thompson JF; Siebert GA; Anissimov YG; Smithers BM; Doubrovsky A; Anderson CD; Roberts MS
Br J Cancer; 2001 Jul; 85(2):157-65. PubMed ID: 11461070
[TBL] [Abstract][Full Text] [Related]
7. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma.
Lindnér P; Doubrovsky A; Kam PC; Thompson JF
Ann Surg Oncol; 2002 Mar; 9(2):127-36. PubMed ID: 11888868
[TBL] [Abstract][Full Text] [Related]
9. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
Ueno T; Ko SH; Grubbs E; Pruitt SK; Friedman HS; Tyler DS
Am J Surg; 2004 Nov; 188(5):532-7. PubMed ID: 15546565
[TBL] [Abstract][Full Text] [Related]
11. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL
Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study.
Kroon HM; Coventry BJ; Henderson MA; Barbour A; Serpell J; Smithers BM; Thompson JF
Eur J Surg Oncol; 2019 May; 45(5):832-837. PubMed ID: 30867095
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy.
Roberts MS; Wu ZY; Siebert GA; Anissimov YG; Thompson JF; Smithers BM
Melanoma Res; 2001 Aug; 11(4):423-31. PubMed ID: 11479432
[TBL] [Abstract][Full Text] [Related]
14. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma.
Papadia F; Basso V; Patuzzo R; Maurichi A; Di Florio A; Zardi L; Ventura E; González-Iglesias R; Lovato V; Giovannoni L; Tasciotti A; Neri D; Santinami M; Menssen HD; De Cian F
J Surg Oncol; 2013 Feb; 107(2):173-9. PubMed ID: 22674435
[TBL] [Abstract][Full Text] [Related]
15. In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats.
van der Veen AH; Seynhaeve AL; Breurs J; Nooijen PT; Marquet RL; Eggermont AM
Br J Cancer; 1999 Feb; 79(3-4):433-9. PubMed ID: 10027309
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Cancer; 2009 May; 115(9):1932-40. PubMed ID: 19288571
[TBL] [Abstract][Full Text] [Related]
17. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
18. Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review.
Kroon HM; Huismans AM; Kam PC; Thompson JF
J Surg Oncol; 2014 Mar; 109(4):348-51. PubMed ID: 24522939
[TBL] [Abstract][Full Text] [Related]
19. Isolated limb perfusion for melanoma.
Kroon BB; Noorda EM; Vrouenraets BC; Nieweg OE
J Surg Oncol; 2002 Apr; 79(4):252-5. PubMed ID: 11920783
[No Abstract] [Full Text] [Related]
20. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
